Correlation between serum decoy receptor 3 and airflow restriction, quality of life, and exacerbations within 1 year in patients with moderate to severe stable COPD
GUO Li, XIE Baimei, WANG Juan
Department of Geriatrics, the 986th Hospital of PLA Air Force, Xi’an 710001, China
Abstract：Objective To investigate the serum Decoy Receptor 3 (DcR3) level in patients with chronic obstructive pulmonary disease (COPD) and to investigate the correlation of DcR3 with airflow restriction, quality of life and acute exacerbations within 1 year. Methods From August 2021 to August 2022, 81 patients with moderate to severe COPD were included as study subjects. Serum DcR3 levels were measured by enzyme-linked immunosorbent assay, and the correlation of serum DcR3 with airflow restriction and quality of life was analyzed by Spearman correlation analysis. The clinical factors influencing acute exacerbations within 1 year were analyzed by binary Logistic regression, and the clinical value of serum DcR3 in predicting acute exacerbations within 1 year was analyzed by receiver operating characteristic (ROC) curve. Results Compared with the serum DcR3≥2.45 ng/ml (median) group, the basophil count in the serum DcR3<2.45 ng/ml group significantly increased (P<0.05), and the number of acute exacerbation and hospitalizations within 1 year significantly decreased (P<0.05). Serum DcR3 was negatively correlated with forced expiratory volume in the first second (FEV1) (r=-0.389), FEV1/forced vital capacity (FVC) (r=-0.610), diffusing capacity of the lungs for carbon monoxide (r=-0.611), and inspiratory volume (IC)/total lung ratio (TLC) (r=-0.862), all P<0.05. There was a positive correlation between serum DcR3 and COPD assessment test (CAT) (r=0.638), visual analogue scale (VAS)-cough (r=0.282), VAS-sputum (r=0.269) and VAS-purulent sputum (r=0.237) scores, all P<0.05. Interleukin (IL)-6 was negatively correlated with 75% of the maximum expiratory flow rate (r=-0.481), and C-reactive protein (CRP) was positively correlated with CAT score (r=0.521), both P<0.05. By binary logistic regression, serum DcR3 was independently correlated with acute exacerbations of COPD within one year (P<0.05).The area under the curve of serum DcR3 in predicting acute exacerbations in COPD patients within 1 year was [0.788 (95%CI: 0.688～0.888)], and the sensitivity (0.689) and specificity (0.833) were the highest when serum DcR3≥2.435 ng/ml. Conclusions Serum DcR3 is associated with airflow restriction, quality of life, disease severity and acute onset within 1 year in COPD patients, and serum DcR3 level has potential as a marker of pathogenesis of COPD patients.
郭丽, 谢柏梅, 王娟. 中重度稳定期COPD患者血清DcR3与气流限制、生活质量和1年内急性发作的相关性[J]. 武警医学, 2024, 35(9): 770-776.
GUO Li, XIE Baimei, WANG Juan. Correlation between serum decoy receptor 3 and airflow restriction, quality of life, and exacerbations within 1 year in patients with moderate to severe stable COPD. Med. J. Chin. Peop. Armed Poli. Forc., 2024, 35(9): 770-776.
Aslani M R, Ghazaei Z, Ghobadi H. Correlation of serum fatty acid binding protein-4 and interleukin-6 with airflow limitation and quality of life in stable and acute exacerbation of COPD[J]. Turk J Med Sci, 2020, 50(2): 337-345.
[2]
Owusuaa C, Leest C, Helfrich G, et al. The development of the ADO-SQ model to predict 1-year mortality in patients with COPD[J]. Palliat Med, 2022, 36(5): 821-829.
Kamal A, Abdelmegeid A K, Gabr M A, et al. Serum decoy receptor 3 (DcR3): a promising biomarker for atopic asthma in children[J]. Immunol Res, 2021, 69(6): 568-575.
Brightling C, Greening N. Airway inflammation in COPD: progress to precision medicine[J]. Eur Respir J, 2019, 54(2): 1900651-1900663.
[9]
Xue Q, Xie Y, He Y, et al. Lung microbiome and cytokine profiles in different disease states of COPD: a cohort study[J]. Sci Rep, 2023, 13(1): 5715-5725.
Ghobadi H, Hosseini N, Aslani M R. Correlations between serum decoy receptor 3 and airflow limitation and quality of life in male patients with stable stage and acute exacerbation of COPD[J]. Lung, 2020, 198(3): 515-523.
2024, Vol. 35 
